Frequently Asked Questions

Semaglutide is a GLP-1 receptor agonist — a class of medication that works with your body's natural appetite-regulating hormones. It signals fullness, slows digestion, and significantly reduces food cravings and 'food noise.' It is the active ingredient in brand-name medications such as Ozempic and Wegovy. At Sarasota Trim Clinic, semaglutide programs are managed by a licensed provider and tailored to your health profile.

Tirzepatide is a dual-action medication that activates both GLP-1 and GIP receptors — two separate appetite and metabolic pathways. Clinical studies have shown tirzepatide to produce significant weight loss in eligible patients. It is the active ingredient in Mounjaro and Zepbound. Your provider will help determine whether semaglutide or tirzepatide is the right fit for your situation.

Semaglutide activates one receptor (GLP-1). Tirzepatide activates two (GLP-1 and GIP), which may result in greater appetite suppression and metabolic impact for some patients. Both medications are administered via a weekly subcutaneous injection. Your provider will discuss the clinical differences and help you choose the most appropriate option based on your health history and goals.

Ozempic and Wegovy both contain semaglutide but are FDA-approved for different indications — Ozempic for type 2 diabetes management, Wegovy for chronic weight management. Similarly, Mounjaro contains tirzepatide approved for diabetes, while Zepbound is approved for chronic weight management. Your provider will discuss your specific situation and medication options during your consultation.

Compounded semaglutide is prepared by a licensed compounding pharmacy and may be used when FDA-approved brand medications are unavailable or cost-prohibitive. Compounded medications are not FDA-approved as finished products, but they are prepared under pharmaceutical standards. Your provider will discuss your specific medication options and their regulatory status during your consultation.

Many patients report reduced appetite and quieter food cravings within the first 2–4 weeks. Meaningful scale results typically become visible by weeks 6–12, as the medication dose is gradually increased. Results vary by individual — your provider will monitor your progress and adjust dosing to support your goals safely.

The most common side effects are gastrointestinal: nausea, bloating, mild stomach discomfort, or constipation — particularly during the early dose-escalation phase. Most patients find these manageable and temporary. Your provider will guide you through dose titration to minimize side effects. Serious adverse events are rare. Contact your provider immediately if you experience severe or unexpected symptoms.

Many patients do use GLP-1 medications as ongoing support rather than a short-term fix. Your provider will discuss your long-term goals and the appropriate duration for your program. We do not pressure you into any timeline.

Research shows that some weight regain is common after stopping GLP-1 medications, as the appetite-regulating effects diminish. This is why we pair medication with education and behavioral support. Your provider will work with you on a long-term plan that reflects your goals and lifestyle — not just a prescription and a goodbye.

Food noise is the constant, intrusive mental chatter about food — the cravings, the impulse to snack even when you're not hungry, the obsession with what you just ate or what you're about to eat. It's driven by brain chemistry, not willpower. GLP-1 medications act on appetite-regulating centers in the brain and gut, and many patients describe the quieting of food noise as one of the most life-changing effects of the medication. For many, food simply becomes less emotionally loaded.

Semaglutide mimics a hormone your gut naturally releases after eating. It signals to your brain that you're full, slows stomach emptying, and reduces the reward signal food typically triggers. Most patients describe it as: eating a small amount and feeling genuinely satisfied, losing interest in food between meals, and noticing that cravings for high-calorie or sugary foods quiet down significantly. It's not a loss of appetite entirely — it's a recalibration.

Not typically. At appropriate doses, most patients still feel hunger — it's just more manageable and easier to satisfy with smaller portions. A small number of patients, particularly at higher doses or during dose increases, may experience reduced appetite to the point where eating enough protein and calories requires intentional effort. Your provider will monitor this and adjust dosing if needed. The goal is healthy, sustainable weight loss — not starvation.

Semaglutide is a once-weekly injection with a half-life of approximately one week, meaning appetite suppression should be consistent throughout the week — not just right after your injection. Tirzepatide follows a similar pattern. Most patients do not experience a clear 'peak and valley' effect, though individual responses vary. If appetite suppression is uneven, discuss timing adjustments with your provider.

Cravings typically reduce significantly — this is one of the most reported and celebrated effects of GLP-1 therapy. Many patients are surprised by how much less they think about food, particularly sweets and highly processed foods. That said, cravings don't always disappear entirely, especially early in treatment or at lower doses. As your dose increases over the first 16–20 weeks, most patients notice a continued improvement in craving control.

Many patients report a meaningful shift in their emotional relationship with food. Foods that once felt urgent or emotionally loaded often feel more neutral. This can be genuinely freeing — but it can also feel unfamiliar at first. Your provider and our patient education resources can help you navigate this change positively, building habits that support long-term success.

Nausea is the most common early side effect and typically peaks during the dose-escalation phase. Practical strategies include: eating smaller, more frequent meals; avoiding greasy, fried, or heavily spiced foods; staying well-hydrated; eating slowly; and not lying down immediately after eating. Most patients find nausea manageable and temporary — it tends to improve significantly after the first few weeks at each new dose level. Your provider can also discuss anti-nausea strategies if needed.

For most patients, nausea, bloating, and gastrointestinal discomfort are most pronounced in the first 2–4 weeks at each new dose level. As your body adjusts, these typically ease. Because doses are increased gradually over 16–20 weeks, side effects can resurface briefly at each step-up. By the time patients reach their maintenance dose, the majority report that GI side effects have reduced significantly or resolved entirely.

Some patients experience temporary hair shedding, known medically as telogen effluvium, during rapid weight loss — regardless of the specific medication. This is typically related to the nutritional and metabolic changes of significant weight loss, not a direct drug effect. Ensuring adequate protein intake (typically 80–100g daily or more) and micronutrient levels can help minimize this. Hair shedding from weight loss is almost always temporary, and hair typically regrows as the body stabilizes.

'Ozempic face' is a colloquial term for facial volume loss that some patients experience during significant weight loss. When the body loses fat, it loses it throughout — including the face — which can result in a hollowed or aged appearance at higher weight loss percentages. This is a general effect of significant weight loss, not unique to semaglutide. Maintaining adequate protein, hydrating well, and losing weight at a gradual pace can reduce the effect. Discuss your aesthetic concerns with your provider.

There is no absolute medical prohibition against moderate alcohol use with semaglutide or tirzepatide — they do not have a dangerous chemical interaction. However, several practical considerations apply: GLP-1 medications slow stomach emptying, which can cause alcohol to be absorbed differently; many patients find they feel the effects of alcohol more quickly or more intensely than before; alcohol also adds empty calories that can slow progress. If you choose to drink, moderation and awareness are key. Discuss your habits with your provider.

All significant weight loss — regardless of method — carries some risk of muscle loss alongside fat loss. GLP-1 medications are no exception. The primary mitigation strategies are: consuming adequate protein (aim for at least 0.7–1g per pound of goal body weight), engaging in resistance exercise, and losing weight at a moderate rather than extreme rate. Your provider will factor this into your program. Preserving muscle mass during weight loss is one of the most important goals of any medically guided program.

Some patients report improved sleep as a secondary benefit of weight loss — particularly those with sleep apnea, which is closely linked to excess weight. A subset of patients may experience mild sleep disruption, vivid dreams, or difficulty falling asleep, particularly early in treatment. These effects are not universally reported and tend to resolve. If sleep disturbances are significant or persistent, discuss this with your provider.

Yes. Constipation is a commonly reported side effect, particularly as doses increase. Semaglutide slows gastric motility, which can affect bowel regularity. Strategies to manage constipation include: increasing water intake, adding fiber to your diet (fruits, vegetables, whole grains), light daily movement, and — if needed — over-the-counter stool softeners or fiber supplements. Your provider can recommend specific options if constipation becomes uncomfortable.

Acute pancreatitis is a rare but serious reported side effect. Symptoms include severe abdominal pain, often radiating to the back, with nausea and vomiting. If you experience sudden severe abdominal pain while on GLP-1 therapy, seek medical attention immediately and contact your provider. Patients with a history of pancreatitis should discuss this with their provider before starting therapy.

Most patients find self-injection straightforward after the first time. Semaglutide and tirzepatide come in pre-filled auto-injector pens — you do not need to handle a syringe or measure a dose. The injection is subcutaneous (just under the skin), using a very fine, short needle. Your provider and the medication packaging include step-by-step instructions. The vast majority of patients who were apprehensive before their first injection report that it is far easier than they expected.

The three recommended injection sites are the abdomen (at least 2 inches from the navel), the outer thigh, and the upper arm. Most patients use the abdomen. Rotating injection sites helps reduce localized irritation or lipodystrophy (changes in fat tissue at injection sites). Your provider will walk you through proper technique.

The needle is very fine and short — most patients describe minimal discomfort, often less than a typical blood draw or flu shot. A brief pinch or slight sting is normal. Injecting at room temperature (rather than cold from the refrigerator) can reduce discomfort. Most patients adapt quickly and describe the weekly injection as a non-event within the first few weeks.

Yes. Semaglutide and tirzepatide injection pens can be stored at room temperature (up to 77°F / 25°C) for a specified period — typically up to 56 days once opened. Unopened pens should be refrigerated. When traveling, a cooling pouch or insulated bag can help if you'll be in warm climates for extended periods. Carry medication in your carry-on when flying — not in checked luggage. Your specific pen's storage instructions will be included with your medication.

Unopened pens should be stored in the refrigerator between 36°F–46°F (2°C–8°C). Once opened or in use, pens can typically be kept at room temperature (up to 77°F) for up to 56 days (Wegovy) — specific storage windows vary by medication. Never freeze GLP-1 medications and keep them away from direct sunlight or heat. Always follow the storage instructions included with your specific prescription.

There is no single required diet. However, your results — and how you feel — will be significantly better with thoughtful eating. Prioritizing protein at every meal helps preserve muscle mass. Avoiding foods that commonly worsen GI side effects (fried, greasy, heavily spiced foods) helps comfort. Staying well-hydrated is essential. Your provider will discuss nutritional guidance during your consultation — we focus on sustainable habits, not rigid restrictions.

Most providers recommend a minimum of 0.7 grams of protein per pound of goal body weight — many recommend closer to 1g per pound of current body weight for patients actively losing weight on GLP-1 therapy. Prioritizing protein at every meal (eggs, meat, fish, Greek yogurt, cottage cheese, legumes, protein shakes) helps protect lean muscle during the weight loss process. Because GLP-1 medications reduce overall appetite and food intake, protein must be a conscious priority — it's easy to undereat it.

Exercise is not a requirement to start the program, but it significantly improves outcomes — particularly for preserving muscle mass, metabolic health, and long-term weight maintenance. Resistance training (weights, bands, bodyweight exercises) is especially valuable. Even light daily movement — walking 20–30 minutes — improves outcomes and general wellbeing. Your provider can help you set realistic, sustainable activity goals based on your current fitness level.

Yes. Foods high in fat, grease, or intense spices commonly worsen nausea and GI discomfort — particularly early in treatment or after dose increases. Very sugary foods and carbonated beverages can also contribute to bloating. Many patients naturally gravitate away from these foods as appetite changes, but being mindful early on can help you feel significantly more comfortable.

Most patients can eat relatively normally — but their definition of 'normal' typically changes. Portion sizes naturally decrease. Some foods that previously appealed may feel less appealing. Early in treatment, overeating or eating too quickly can reliably trigger nausea. Eating mindfully, chewing thoroughly, stopping when satisfied, and avoiding trigger foods is the practical approach. Most patients adjust within the first few weeks and feel well at their new, smaller portion sizes.

Clinical trials show average weight loss of approximately 12–15% of body weight with semaglutide (Wegovy) over 68 weeks — roughly 35–40 lbs for a 250-lb patient. Tirzepatide (Zepbound) has shown even greater average results in trials, with some participants losing more than 20% of body weight. Individual results vary significantly based on adherence, dose, lifestyle factors, and health profile. Your provider will set realistic, personalized expectations during your consultation.

A weight loss plateau is typically defined as losing less than one pound over four or more consecutive weeks, despite continued adherence. Plateaus are physiologically normal — as you lose weight, your body's energy needs decrease and it adapts. Plateaus often occur at months 3–6 and affect roughly 70% of patients at some point. Strategies include: reassessing protein and calorie intake, increasing physical activity (especially resistance training), ensuring adequate sleep, discussing a dose adjustment with your provider, and staying consistent. Plateaus are temporary — not failures.

Not necessarily. Many patients use GLP-1 therapy as a long-term tool — similar to how blood pressure medication is used chronically. Others use it for a defined period to achieve a goal weight and then transition off with a maintenance strategy. Research does show that weight regain is common after stopping, particularly without lifestyle changes in place. Your provider will help you set goals and discuss what a realistic long-term plan looks like for your specific situation.

Studies show that most patients regain a significant portion of lost weight — often two-thirds within a year — after stopping GLP-1 therapy, as appetite returns and the medication's effects on the brain diminish. This is why the lifestyle habits you build while on the medication are so important. Stopping does not have to mean failure — it requires a thoughtful transition plan, which your provider will help you develop.

Any significant weight loss causes some degree of metabolic adaptation — the body becomes more efficient and burns slightly fewer calories at rest. This is one reason plateaus occur and why weight maintenance requires ongoing attention. GLP-1 medications do not appear to dramatically worsen metabolic adaptation compared to other weight loss methods. Preserving muscle through resistance exercise and adequate protein is the most effective way to protect your metabolic rate during weight loss.

Some patients do successfully maintain meaningful weight loss after stopping — particularly those who have built strong dietary habits, established regular exercise routines, and lost weight gradually. The key factors are muscle preservation, protein prioritization, consistent movement, and having a clear maintenance strategy. Your provider will work with you on a transition plan if and when you decide to discontinue therapy. There is no one-size-fits-all answer, and there is no shame in choosing to stay on therapy long-term.

Clinical trials suggest tirzepatide (Mounjaro / Zepbound) produces greater average weight loss than semaglutide (Wegovy) — roughly 20%+ of body weight vs. 12–15%. Tirzepatide is a dual-action medication that activates both GLP-1 and GIP receptors, which may explain its enhanced efficacy. However, individual response varies. Some patients do better on semaglutide; others find tirzepatide a stronger fit. Your provider will discuss the most appropriate option based on your health profile and goals.

Older weight loss medications primarily worked by stimulating the central nervous system to suppress appetite or by blocking fat absorption. GLP-1 medications work through a fundamentally different mechanism — targeting the gut-brain axis, regulating insulin, slowing gastric emptying, and reducing the neurological reward response to food. They tend to produce greater weight loss, are better tolerated, and carry meaningful cardiovascular benefits in addition to weight reduction.

Yes — when the underlying clinical care is equivalent. Telehealth allows licensed providers to evaluate your health history, create personalized plans, adjust dosing, and monitor your progress just as they would in person. Multiple studies confirm that telehealth chronic disease management produces outcomes comparable to in-person care. The advantage of telehealth is convenience, privacy, and consistency — particularly important for a program that requires regular follow-up over months.

Direct-to-consumer services often involve minimal clinical evaluation — a brief online intake form — and limited ongoing oversight. A medically guided program involves a licensed provider who reviews your full health history, discusses your goals, monitors your progress, adjusts your treatment, and is available when questions arise. The difference matters: GLP-1 medications are not without risks, and individualized medical oversight is what makes a program safe and effective — not just a subscription box.

Generally, adults with a BMI of 27 or higher with at least one weight-related health condition, or a BMI of 30 or higher, may be appropriate candidates for GLP-1 programs. However, eligibility is determined by your provider during your consultation — it's never based on BMI alone. Your full health history, current medications, and goals all factor into the evaluation.

Lab work is not always required to begin, but your provider may request recent bloodwork or health records depending on your health history, current medications, and the specific treatment being considered. Your provider will tell you exactly what is needed after your consultation.

Certain health conditions — including a personal or family history of medullary thyroid carcinoma, multiple endocrine neoplasia syndrome type 2, pancreatitis, or specific kidney conditions — may make GLP-1 medications inappropriate. Your provider will conduct a thorough review of your health history during your consultation to determine safe eligibility.

Wegovy (semaglutide 2.4 mg weekly) is FDA-approved for chronic weight management in adults with obesity or overweight with at least one weight-related condition. Ozempic is approved for type 2 diabetes. Compounded semaglutide is not an FDA-approved finished product. Your provider will discuss your specific medication and its regulatory status during your consultation.

Certain medications may interact with GLP-1 therapy. Your provider will review all current medications during your consultation to ensure there are no contraindications. Always be transparent about your full medication list, including supplements and over-the-counter products.

No. Individual results vary significantly based on health profile, adherence, metabolism, lifestyle, and other factors. We do not guarantee specific outcomes. Our goal is to provide the best possible medical support for your journey — and honest, transparent guidance throughout.

Book a free telehealth consultation at the link above or call 239-422-6350. Your provider will review your health history, discuss your goals, and determine the most appropriate next steps. Most patients receive their personalized plan within days.

Your initial consultation is free. There is no charge to speak with a licensed provider about whether this program is right for you.

No. Every step — consultation, treatment plan, and medication delivery — is 100% telehealth. You never need to leave your home.

No referral is needed. However, depending on your health history, your provider may request recent lab work or medical records to ensure your plan is built on complete information.

Medical weight loss programs start at $149/month — all-inclusive, no hidden fees, no membership costs, no mandatory upsells. Shipping is always free. Program options and medication details are discussed during your consultation.

No. We believe in complete pricing transparency. What you see is what you pay. Shipping is included. There are no surprise charges.

Medication typically ships from a U.S.-based licensed pharmacy and arrives in 1–2 business days. Your provider will provide specific shipping expectations based on your prescription.

Yes. We do not lock you into long-term contracts. Contact us any time to discuss pausing or canceling your program.

Almost certainly, yes. Our 1–2 day shipping has a significant head start on Sarasota bridge traffic. (We looked into it — there is no cure for that particular situation. But we can help with the other thing.)

Yes. Sarasota Trim Clinic serves both year-round residents and seasonal visitors throughout Florida. If you are present in Florida during your consultation, we can evaluate your eligibility and begin your program during your stay.

Telehealth medical practices are governed by state licensing laws. We encourage you to discuss your travel plans with your provider during your consultation so we can map out the most appropriate continuity of care options. Cross-state prescription continuity depends on provider licensure in your home state.

Medication shipping and prescribing is subject to applicable state laws and provider licensure. Discuss your travel schedule with your provider — they will advise on what is possible and legal for your specific situation.

You connect with a licensed provider via a secure video or phone call. They review your health history, create your personalized treatment plan, and your medication (if prescribed) ships directly to your door — free. No driving, no waiting rooms.

Yes. Telehealth medicine is legal, regulated, and widely practiced across the United States. Our providers are licensed professionals who follow established medical protocols. Your safety and clinical accuracy are the top priorities at every step.

A smartphone, tablet, or computer with a camera and internet connection. We use HIPAA-compliant platforms for all consultations.

Absolutely. We comply with all applicable HIPAA privacy regulations. Your information is never sold, shared without your consent, or used for marketing purposes.

Most local medspas and weight loss clinics require in-person visits, charge separate consultation fees, or operate on a membership model. Sarasota Trim Clinic is 100% telehealth, all-inclusive at $149/month, with free delivery. No drives across town in season. No waiting rooms. No membership traps.

Diet apps and programs are self-directed. We are a medical practice. Your program is created and monitored by a licensed provider who may prescribe medication where appropriate. This is clinical support — not a calorie counter.

Yes. Sarasota Trim Clinic is proudly affiliated with South Florida Trim Clinic — the same provider network, the same patient education ecosystem, and the same standard of care that has served Gulf Coast communities for years.

Yes. We serve all of Sarasota County and surrounding Gulf Coast communities — Bradenton, Venice, Lakewood Ranch, Englewood, North Port, Siesta Key, Longboat Key, Osprey, Nokomis, Palmer Ranch, Gulf Gate, Palmetto, and Parrish.

Food noise is the constant, intrusive mental chatter about food — the cravings, the second-guessing, the guilt. It is a real physiological phenomenon driven by brain chemistry, not willpower. GLP-1 medications work on the brain's appetite centers and can dramatically reduce food noise for many patients.

Visit our patient library at eliminatethefoodnoiseinyourhead.com/library for plain-language education on semaglutide, tirzepatide, food noise, and what to expect. It's free, no login required.

Yes. Completely free. No subscription, no account required. We believe medical education should be accessible to everyone.

We work with licensed U.S.-based pharmacies. Some medications used in our programs are FDA-approved for weight management; others may be compounded alternatives. Your provider will discuss your specific medication and its regulatory status during your consultation. We do not make blanket claims across all program options.

We comply fully with HIPAA regulations. Your health information is never sold or shared without your consent. Our full Privacy Policy is available in the footer of this website.

All legal documents — Privacy Policy, Terms of Use, Disclaimer, Testimonials Disclosure, and Linking Policy — are linked in the footer of every page.